Vitamin D in Human Serum with Roche e801
Detection of Vitamin D in Human Serum with Roche e801
|Test Name:||Immunoassay is intended for the quantitative determination of total 25-hydroxyvitamin D in human serum and plasma.|
|Method Name:||The Elecsys Vitamin D total II assay employs a vitamin D binding protein (VDBP) labeled with a ruthenium complex as capture protein to bind 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2. Cross reactivity to 24,25-dihydroxyvitamin D is blocked by a specific monoclonal antibody (rabbit).|
|Results:||Technical Range: 5.0-100 ng/mL
Reportable Range: 5.0-94.9 ng/mL
|Reference Ranges:||30-100 ng/mL|
|Clinical Significance:||Vitamin D is a fat-soluble steroid hormone precursor that is mainly produced in the skin by exposure to sunlight. Vitamin D is biologically inert and must undergo two successive hydroxylations in the liver and kidney to become the biologically active 1,25-dihydroxyvitamin D.
The two most important forms of vitamin D are vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol). In contrast to vitamin D3, the human body cannot produce vitamin D2 which is taken up with fortified food or given by supplements. In human plasma vitamin D3 and D2 are bound to the vitamin D binding protein and transported to the liver where both are hydroxylated to form 25-hydroxyvitamin D. It is commonly agreed that 25-hydroxyvitamin D is the metabolite to determine the overall vitamin D status as it is the major storage form of vitamin D in the human body. This primary circulating form of vitamin D is biologically inactive with levels approximately 1000 fold greater than the circulating 1,25-dihydroxyvitamin D. The half-life of circulating 25-hydroxyvitamin D is 2 3 weeks.
Most of the 25-hydroxyvitamin D, measurable in serum, is 25-hydroxyvitamin D3 whereas 25-hydroxyvitamin D2 reaches measurable levels only in patients taking vitamin D2 supplements. Vitamin D2 is considered to be less effective.
The most abundant product of 25-hydroxyvitamin D catabolism by 24 hydroxylase (CYP24A1) is 24,25-dihydroxyvitamin D. It accounts for 2 20 % of the total circulating 25-hydroxyvitamin D, has a half-life of approximately 7 days and is present in serum at concentrations of up to approximately 10 nmol/L. Vitamin D is essential for bone health. In children, severe deficiency leads to bone-malformation, known as rickets. Milder degrees of insufficiency are believed to cause reduced efficiency in the utilization of dietary calcium. Vitamin D deficiency causes muscle weakness; in elderly, the risk of falling has been attributed to the effect of vitamin D on muscle function.
Vitamin D deficiency is a common cause of secondary hyperparathyroidism. Elevations of parathyroid hormone levels, especially in elderly vitamin D deficient adults can result in osteomalacia, increased bone turnover, reduced bone mass and risk of bone fractures. Low 25-hydroxyvitamin D concentrations are also associated with lower bone mineral density. In conjunction with other clinical data, the results may be used as an aid in the assessment of bone metabolism.
|Submission Criteria:||For specimen collection and preparation, only use suitable tubes or collection containers.
Only the specimens listed below were tested and found acceptable.
Serum Plasma: Li-heparin and K2-EDTA plasma
Do not use fluoride plasma
The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, therefore not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases.
|Rejection Criteria:||Rejection criteria include but are not limited to:
1. Specimens containing fibrin or clots.
2. Excessive platelet clumping
3. Leaking specimens
4. Substandard mixing or collection
5. Expired or improperly stored collection tubes.
6. Improperly filled tubes based on collection tube manufacturer’s guidelines.
7. Contaminated specimens (IV fluid, foreign particles, etc.)
8. Specimens not analyzed within the appropriate time frame.
9. Samples not shipped at appropriate temperature.
10. Samples without 2 proper identifiers or samples having identifiers that do not match the electronic or paper lab requisition.
|Authorization:||Diagnostic testing can only be performed with approval from an authorized provider/agency.|
|Turn Around Time:||1 day.|